Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the phase Ib TATTON study Meeting Abstract
| Authors: | Ramalingam, S. S.; Saka, H.; Ahn, M. J.; Yu, H.; Horn, L.; Hida, T.; Cantarini, M.; Verheijen, R.; Wessen, J.; Oxnard, G.; Ohe, Y. |
| Abstract Title: | Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the phase Ib TATTON study |
| Meeting Title: | 110th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 79 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2019 Mar 29-Apr 3 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-07-01 |
| Language: | English |
| ACCESSION: | WOS:000488129900030 |
| DOI: | 10.1158/1538-7445.Am2019-ct034 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT034 -- Source: Wos |
